Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/624866

Prostate-Specific Antigen Dynamics Predict Individual Responses to Intermittent Androgen Deprivation

Brady, R.·Nagy, J.·Gerke, T.·Zhang, T.·Wang, A. Z.·Zhang, J.·Gatenby, R.·Enderling, H.
View original source ↗Export metadata ↓

Abstract

BackgroundIntermittent androgen deprivation therapy (IADT) is an attractive treatment approach for biochemically recurrent prostate cancer (PCa), whereby cycling treatment on and off can reduce cumulative dose, limit toxicities, and delay development of treatment resistance. To optimize treatment within the context of ongoing intratumoral evolution, underlying mechanisms of resistance and actionable biomarkers need to be identified.\n\nMethodsWe have developed a quantitative framework to simulate enrichment of prostate cancer stem cell (PCaSC) dynamics during treatment as a plausible mechanism of resistance evolution.\n\nResultsSimulated dynamics of PCaSC and non-stem cancer cells demonstrate that stem cell proliferation patterns correlate with longitudinal serum prostate-specific antigen (PSA) measurements in 70 PCa patients undergoing multiple cycles of IADT. By learning the dynamics from each treatment cycle, individual model simulations predict evolution of resistance in the subsequent IADT cycle with a sensitivity and specificity of 57% and 94%, respectively and an overall accuracy of 90%. Additionally, we evaluated the potential benefit of docetaxel for IADT in biochemically recurrent PCa. Model simulations based on response dynamics from the first IADT cycle identify patients who would or would not benefit from concurrent docetaxel in subsequent cycles.\n\nConclusionOur results demonstrate the feasibility and potential value of adaptive clinical trials guided by patient-specific mathematical models of intratumoral evolutionary dynamics continuously updated with each treatment cycle.\n\nTranslational RelevanceCompared to continuous androgen deprivation therapy, intermittent androgen deprivation (IADT) has been shown to reduce toxicity and delay time to progression in prostate cancer. While numerous mathematical models have been developed to study the response to both continuous and intermittent androgen deprivation, very few have identified actionable biomarkers of resistance and exploited them to predict how patients will or will not respond to subsequent treatment. Here, we identify prostate-specific antigen (PSA) dynamics as the first such biomarker. Mechanistic mathematical modeling of prostate cancer stem cell dynamics that dictate prostate-specific antigen serum levels predicts individual responses to IADT with 90% overall accuracy and can be used to develop patient-specific adaptive treatment protocols, and potentially identify patients that may benefit from concurrent chemotherapy. Model results demonstrate the feasibility and potential value of adaptive clinical trials guided by patient-specific mathematical models of intratumoral evolutionary dynamics continuously updated with each treatment cycle.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Brady, R., Nagy, J., Gerke, T., Zhang, T., Wang, A. Z., Zhang, J., Gatenby, R., Enderling, H.. 2019-05-02. Prostate-Specific Antigen Dynamics Predict Individual Responses to Intermittent Androgen Deprivation. https://doi.org/10.1101/624866

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

The methionine cycle sustains the mesenchymal phenotype of tumor cells and drives PDA progression

Mesenchymal traits are associated with poor prognosis in Pancreatic Ductal Adenocarcinoma (PDA), but direct targeting of mesenchymal tumor cells remains a challenge. Metabolic profiling of tumor cells isolated from murine PDA and liver metastases (LM) revealed that LM rely more on the methionine cycle than does primary PDA. This metabolic shift was specifically associated with increased activation of the methionine cycle in mesenchymal tumor cells compared to differentiated tumor cells. We show that the targeting of the key enzyme of the methionine cycle S-adenosylhomocysteine hydrolase (SAHH) in mesenchymal cells lowers the levels of homocysteine (Hcy) and glutathione, resulting in reduced antioxidant capacity, deregulated intracellular calcium homeostasis, and ultimately loss of mesenchymal markers. Together, these events decrease cell proliferation and invasion, blunting the tumorigenic and metastatic potential of SAHH-deficient cells, eventually impeding tumor growth and progression of the metastatic disease. Clinically, the high expression of SAHH in patients with mesenchymal PDA is correlated with poor survival, positioning SAHH as a potential therapeutic target to impede the pro-metastatic, mesenchymal phenotype of PDA.

cancer biology↗
bioRxiv2026

Arrest-associated transcriptional programmes outweigh apoptosis-associated programmes in treatment-naive pancreatic ductal adenocarcinoma

Background: Pancreatic ductal adenocarcinoma (PDAC) is driven by mutant KRAS, and RAS inhibitors now extend survival in previously treated metastatic disease. Whether treatment shrinks a tumour or only halts its growth depends partly on whether cancer cells die or stop dividing, yet how untreated PDAC cells are balanced between these programmes is unknown. Aims: We aimed to characterise the balance between apoptosis-associated and arrest-associated transcriptional programmes in treatment-naive PDAC and to examine their relationships with tumour subtype, TGM2 expression, tissue organisation, survival and drug sensitivity. Methods and results: We scored 52,999 malignant cells from 18 untreated patients in the Hwang atlas using a transcriptional contrast between genes associated with apoptosis and genes associated with resistance to apoptosis or cell-cycle arrest. In every patient the contrast was shifted toward the arrest-associated side: using equality between the two sides as the dividing threshold, 86.3% of cells with an informative score fell on that side, although the proportion depends on the threshold chosen. The shift recurred in the independent Steele atlas (median 71.6% per sample, range 37.1% to 90.8%). In the discovery cohort, tumours with higher basal-like scores had fewer arrest-side cells, and TGM2 expression was modestly higher on the arrest-associated side in both cohorts. The contrast did not track cell-line drug sensitivity or survival in bulk tumours. Conclusion: Untreated PDAC cells show a reproducible transcriptional bias toward anti-apoptotic and cell-cycle-arrest programmes. Whether this bias predicts cellular responses to treatment remains to be tested.

cancer biology↗
bioRxiv2026

Quantitative live imaging reveals region-dependent medulloblastoma disseminationin the zebrafish brain

Medulloblastoma is the most common malignant pediatric brain tumor, and relapse is frequently driven by dissemination within the central nervous system. Yet the early dynamics of tumor spread remain difficult to resolve in vivo. Here, we orthotopically transplanted human medulloblastoma cells into larval zebrafish and followed individual xenografts by longitudinal high-resolution confocal imaging. ONS-76 showed particularly robust dissemination, with hindbrain tumors spreading into the developing cerebellum in 81.5% of larvae, more than fourfold the frequency observed for forebrain or midbrain tumors. Disseminating cells extended along brain-surface and leptomeningeal-like regions and frequently associated with cerebral vasculature. Quantitative analysis of tumor area, perimeter, compactness, convex hull area, and fractal dimension captured changes in growth and spatial complexity over time. Dasatinib reduced tumor expansion and dissemination-related features in a concentration-dependent manner, while higher doses revealed host toxicity. These findings establish a powerful in vivo model for resolving medulloblastoma dissemination and therapeutic response.

cancer biology↗